Prescription medicine
Lopinavir and ritonavir Brand names: Kaletra
Lopinavir and ritonavir (Kaletra) is a prescription medicine with an FDA approval on record since 2000. FDA's NDC Directory lists it from 3 generic labelers, and pharmacies paid $4.46 per lopinavir-ritonavr 200-50 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- A presentation discontinued
Check it at the source: the lopinavir and ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.); the NDA 21251 record on Drugs@FDA; every lopinavir and ritonavir label on DailyMed.
Highlights of the record
FDA label of July 23, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageKALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 14 days and older.
Forms and strengths
- 80 mg/ml / 20 mg/ml
- 100 mg / 25 mg
- 200 mg / 50 mg
Film-coated tablet; solution.
On the market
- Earliest approval on file
- September 15, 2000 Kaletra, Abbvie; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 6 first December 27, 2016; 5 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 4 of which 3 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $4.46 per tablet Lopinavir-ritonavr 200-50 mg tablet
- Shortage (FDA)
- None current 3 past records
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 13,476 through July 30, 2026
What is lopinavir and ritonavir used for?
From the label: indications and usageKALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 14 days and older. Limitations of Use: Genotypic or phenotypic testing and/or treatment history should guide the use of KALETRA. The number of baseline lopinavir resistance-associated substitutions affects the virologic response to KALETRA [see Microbiology ( 12.4 )]. KALETRA is an HIV-1 protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients (14 days and older).
Conditions named in the indications of lopinavir and ritonavir's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Cytochrome P450 3A Inhibitor and Protease Inhibitor.
Source: FDA drug label (Kaletra), AbbVie Inc., effective July 23, 2026 (SPL set 8290add3-4449-4e58-6c97-8fe1eec972e3), via openFDA; the full label on DailyMed
What does the patient leaflet for lopinavir and ritonavir say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about KALETRA?KALETRA may cause serious side effects, including: Interactions with other medicines. It is important to know the medicines that should not be taken with KALETRA. For more information, see "Who should not take KALETRA?” Side Effects in babies taking KALETRA oral solution. KALETRA oral solution contains alcohol (ethanol) and propylene glycol. Call your healthcare provider right away if your baby appears too sleepy or their breathing changes. Inflammation of your pancreas (pancreatitis). KALETRA can cause pancreatitis which may be serious and may lead to death. People who have high levels of a certain fat (triglycerides) have a risk for developing pancreatitis. If you have advanced HIV-1 disease, you may have an increased risk of high triglyceride levels in your blood, and pancreatitis. If you have a history of pancreatitis, you may have an increased risk of it coming back again during treatment with KALETRA. Tell your healthcare provider if you have any signs or symptoms of pancreatitis including: ° nausea ° vomiting ° stomach-area (abdominal) pain Liver problems. Liver problems, including death, can happen in people who take KALETRA. Your healthcare provider should do blood tests before and during your treatment with KALETRA to check your liver function. If you have Hepatitis B or Hepatitis C, or other liver problems, you may have an increased risk for developing new or worsening of liver problems during treatment with KALETRA. Tell your healthcare provider right away if you have any signs and symptoms of liver problems including: ○ loss of appetite ○ yellow skin and whites of eyes (jaundice) ○ dark-colored urine ○ pale colored stools ○ itchy skin ○ stomach area (abdominal) pain Changes in your heart rhythm and the electrical activity of your heart. […]
From the patient leaflet: How should I store KALETRA?KALETRA tablets: Store KALETRA tablets at room temperature, between 68°F to 77°F (20°C to 25°C). Store KALETRA tablets in the original container. Do not keep KALETRA tablets out of the container it comes in for longer than 2 weeks, especially in areas where there is a lot of humidity. Keep the container closed tightly. KALETRA oral solution: Store KALETRA oral solution in a refrigerator, between 36°F to 46°F (2°C to 8°C). KALETRA oral solution that is kept refrigerated may be used until the expiration date printed on the label. KALETRA oral solution that is stored at room temperature less than 77°F (25°C) should be used within 2 months. Keep KALETRA oral solution away from high heat. Throw away any medicine that is out of date or that you no longer need. Keep KALETRA and all medicines out of the reach of children.
Source: FDA drug label (Kaletra), AbbVie Inc., effective July 23, 2026 (SPL set 8290add3-4449-4e58-6c97-8fe1eec972e3), via openFDA; the full label on DailyMed
Is there a generic for lopinavir and ritonavir (Kaletra)?
The FDA approved the first generic lopinavir and ritonavir on December 27, 2016. 6 generic applications are approved; 5 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 5 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists lopinavir and ritonavir from 3 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2000 earliest approval on file
- 2016 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for lopinavir and ritonavir (Kaletra)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $4.46 per Lopinavir-ritonavr 200-50 mg tablet, down 8% from $4.85 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Lopinavir-ritonavr 200-50 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Lopinavir-ritonavr 200-50 mg tablet | Generic | $4.46 per tablet | $133.95 | -8% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is lopinavir and ritonavir in shortage?
No lopinavir and ritonavir presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 3 records are all marked to be discontinued, the latest updated July 24, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Kaletra, Oral Solution, 80 mg/1 mL; 20 mg/1 mL (NDC 0074-3956-46) | AbbVie Inc. | To Be Discontinued | July 24, 2026 |
| Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-3008-60) | AbbVie Inc. | To Be Discontinued | July 24, 2026 |
| Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-4014-12) | AbbVie Inc. | To Be Discontinued | July 24, 2026 |
Every lopinavir and ritonavir presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
What does the lopinavir and ritonavir label say about other medicines?
The lopinavir and ritonavir label names 105 other medicines in its interaction, contraindication or warning sections. The labels of 43 other medicines name lopinavir and ritonavir. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Abacavir | drug interactions | Concomitant Drug Class/Drug Name: Nucleoside Reverse Transcriptase Inhibitors: abacavir zidovudine; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ abacavir ↓ zidovudine; Clinical Comments: The clinical significance of this potential interaction is unknown. |
| Abemaciclib | drug interactions | Concomitant Drug Class/Drug Name: Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ anticancer agents ↓lopinavir/ritonavir #; … |
| Alfuzosin | contraindications | Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA … |
| Amiodarone | drug interactions | Concomitant Drug Class/Drug Name: Antiarrhythmics e.g. amiodarone, bepridil, lidocaine (systemic), quinidine; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ antiarrhythmics; Clinical Comments: Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics … |
| Apalutamide | contraindications | Anticancer Agents: apalutamide Antimycobacterial: rifampin Herbal Products: St. John's Wort (hypericum perforatum) Hypersensitivity to KALETRA (e.g., toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, urticaria, angioedema) or any of its ingredients, including ritonavir. … |
| Atazanavir | warnings and precautions | The impact on the PR interval of co-administration of KALETRA with other drugs that prolong the PR interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. |
| Atorvastatin | drug interactions | Concomitant Drug Class/Drug Name: Lipid-modifying agents HMG-CoA Reductase Inhibitors: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide; … |
| Atovaquone | drug interactions | Concomitant Drug Class/Drug Name: Antiparasitic: atovaquone; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ atovaquone; Clinical Comments: Clinical significance is unknown; however, increase in atovaquone doses may be needed. |
| Avanafil | drug interactions | Concomitant Drug Class/Drug Name: PDE5 inhibitors: avanafil, sildenafil, tadalafil, vardenafil; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ avanafil ↑ sildenafil ↑ tadalafil ↑ vardenafil; … |
| Azithromycin | drug interactions | Based on known metabolic profiles, clinically significant drug interactions are not expected between KALETRA and dapsone, trimethoprim/sulfamethoxazole, azithromycin, erythromycin, or fluconazole. |
| Beclomethasone | drug interactions | … can increase the risk for Cushing’s syndrome and adrenal suppression. Alternative corticosteroids including beclomethasone and prednisolone (whose PK and/or PD are less affected by strong CYP3A inhibitors relative to other studied steroids) should be considered, particularly for long-term use. |
| Bedaquiline | drug interactions | Concomitant Drug Class/Drug Name: Antimycobacterial: bedaquiline; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ bedaquiline; Clinical Comments: Bedaquiline should only be used with KALETRA if the benefit of co-administration outweighs the risk. |
| Betamethasone | drug interactions | Concomitant Drug Class/Drug Name: Systemic/Inhaled/ Nasal/Ophthalmic Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ lopinavir ↑ glucocorticoids; … |
| Bosentan | drug interactions | Concomitant Drug Class/Drug Name: Endothelin Receptor Antagonists: bosentan; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ bosentan; Clinical Comments: Co-administration of bosentan in patients on KALETRA: In patients who have been receiving KALETRA for at least 10 days, start bosentan at 62.5 mg once … |
Every other medicine the lopinavir and ritonavir label names
| Medicine named | Section | What the label says |
|---|---|---|
| Budesonide | drug interactions | Concomitant Drug Class/Drug Name: Systemic/Inhaled/ Nasal/Ophthalmic Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone … |
| Bupropion | drug interactions | Concomitant Drug Class/Drug Name: Antidepressant: bupropion; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ bupropion ↓ active metabolite, hydroxybupropion; … |
| Carbamazepine | drug interactions | Concomitant Drug Class/Drug Name: Anticonvulsants: carbamazepine, phenobarbital, phenytoin; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ lopinavir ↓ phenytoin; … |
| Ciclesonide | drug interactions | Concomitant Drug Class/Drug Name: Systemic/Inhaled/ Nasal/Ophthalmic Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone … |
| Clarithromycin | drug interactions | Concomitant Drug Class/Drug Name: Anti-infective: clarithromycin; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ clarithromycin; … |
| Colchicine | contraindications | Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine … |
| Cyclosporine | drug interactions | Concomitant Drug Class/Drug Name: Immunosuppressants: e.g. cyclosporine, tacrolimus, sirolimus; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ immunosuppressants; … |
| Dapsone | drug interactions | Based on known metabolic profiles, clinically significant drug interactions are not expected between KALETRA and dapsone, trimethoprim/sulfamethoxazole, azithromycin, erythromycin, or fluconazole. |
| Dasatinib | drug interactions | Concomitant Drug Class/Drug Name: Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine; … |
| Desipramine | drug interactions | … studies reveal no clinically significant interaction between KALETRA and desipramine (CYP2D6 probe), etravirine, pitavastatin, pravastatin, stavudine, lamivudine, omeprazole, raltegravir, ranitidine … |
| Dexamethasone | drug interactions | Concomitant Drug Class/Drug Name: Systemic/Inhaled/ Nasal/Ophthalmic Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone … |
| Digoxin | warnings and precautions | … interval (including calcium channel blockers, beta-adrenergic blockers, digoxin and atazanavir) has not been evaluated. |
| Dihydroergotamine | contraindications | … colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral … |
| Disulfiram | drug interactions | Concomitant Drug Class/Drug Name: Disulfiram/metronidazole; Clinical Comments: KALETRA oral solution contains ethanol, which can produce disulfiram-like reactions when co-administered with disulfiram … |
| Dronedarone | contraindications | Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine … |
| Efavirenz | drug interactions | Concomitant Drug Class/Drug Name: Non-nucleoside Reverse Transcriptase Inhibitors: efavirenz*, nevirapine*; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ lopinavir; … |
| Elagolix | drug interactions | Concomitant Drug Class/Drug Name: GnRH Receptor Antagonists: elagolix; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ elagolix ↓ lopinavir/ritonavir; … |
| Elbasvir and grazoprevir | contraindications | Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine … |
| Encorafenib | drug interactions | Concomitant Drug Class/Drug Name: Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine; … |
| Ergotamine | contraindications | … colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral … |
| Erythromycin | drug interactions | Based on known metabolic profiles, clinically significant drug interactions are not expected between KALETRA and dapsone, trimethoprim/sulfamethoxazole, azithromycin, erythromycin, or fluconazole. |
| Etravirine | drug interactions | … significant interaction between KALETRA and desipramine (CYP2D6 probe), etravirine, pitavastatin, pravastatin, stavudine, lamivudine, omeprazole, raltegravir, ranitidine, or rilpivirine. |
| Felodipine | drug interactions | Concomitant Drug Class/Drug Name: Dihydropyridine Calcium Channel Blockers: e.g. felodipine, nifedipine, nicardipine; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ dihydropyridine … |
| Fentanyl | drug interactions | Concomitant Drug Class/Drug Name: Analgesics Opioid: methadone* fentanyl Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine; … |
| Fluconazole | drug interactions | Based on known metabolic profiles, clinically significant drug interactions are not expected between KALETRA and dapsone, trimethoprim/sulfamethoxazole, azithromycin, erythromycin, or fluconazole. |
| Fluticasone | drug interactions | Concomitant Drug Class/Drug Name: Systemic/Inhaled/ Nasal/Ophthalmic Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone … |
| Fostamatinib | drug interactions | Concomitant Drug Class/Drug Name: Kinase Inhibitors: fostamatinib (also see anticancer agents above); Effect on Concentration of Lopinavir or Concomitant Drug: ↑ fostamatinib metabolite R406; … |
| Glecaprevir and pibrentasvir | drug interactions | Hepatitis C direct acting antivirals: boceprevir* glecaprevir/pibrentasvir simeprevir sofosbuvir/velpatasvir/voxilaprevir ombitasvir/paritaprevir/ ritonavir and dasabuvir* ↓ lopinavir ↓ boceprevir ↓ … |
| Ibrutinib | drug interactions | Concomitant Drug Class/Drug Name: Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine; … |
| Isavuconazonium | drug interactions | Concomitant Drug Class/Drug Name: Antifungals: ketoconazole*, itraconazole, voriconazole isavuconazonium sulfate*; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ ketoconazole ↑ … |
| Itraconazole | drug interactions | Concomitant Drug Class/Drug Name: Antifungals: ketoconazole*, itraconazole, voriconazole isavuconazonium sulfate*; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ ketoconazole ↑ … |
| Ivosidenib | drug interactions | Concomitant Drug Class/Drug Name: Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine; … |
| Ketoconazole | drug interactions | Although not observed in the KALETRA/ketoconazole drug interaction study, co-administration of KALETRA and other drugs that inhibit CYP3A may increase lopinavir plasma concentrations. |
| Lamivudine | drug interactions | … (CYP2D6 probe), etravirine, pitavastatin, pravastatin, stavudine, lamivudine, omeprazole, raltegravir, ranitidine, or rilpivirine. |
| Lamotrigine | drug interactions | Concomitant Drug Class/Drug Name: Anticonvulsants: lamotrigine, valproate; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ lamotrigine ↓ or ↔ valproate; … |
| Lidocaine | drug interactions | Concomitant Drug Class/Drug Name: Antiarrhythmics e.g. amiodarone, bepridil, lidocaine (systemic), quinidine; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ antiarrhythmics; … |
| Lomitapide | contraindications | … simvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® … |
| Lovastatin | contraindications | … acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide Non-opioid Analgesic (selective … |
| Lurasidone | contraindications | Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine … |
| Maraviroc | drug interactions | Concomitant Drug Class/Drug Name: HIV CCR5 – Antagonist: maraviroc*; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ maraviroc; … |
| Methadone | drug interactions | Concomitant Drug Class/Drug Name: Analgesics Opioid: methadone* fentanyl Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine; … |
| Methylergonovine | contraindications | … lurasidone, pimozide Ergot Derivatives: dihydroergotamine, ergotamine, methylergonovine GI Motility Agent: cisapride Hepatitis C direct acting antiviral: elbasvir/grazoprevir HMG-CoA Reductase … |
| Methylprednisolone | drug interactions | … e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; … |
| Metronidazole | drug interactions | Concomitant Drug Class/Drug Name: Disulfiram/metronidazole; Clinical Comments: KALETRA oral solution contains ethanol, which can produce disulfiram-like reactions when co-administered with disulfiram … |
| Midazolam | contraindications | … arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated with drugs that are potent CYP3A inducers where significantly reduced lopinavir plasma … |
| Mometasone | drug interactions | … budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ lopinavir ↑ glucocorticoids; … |
| Nelfinavir | drug interactions | Concomitant Drug Class/Drug Name: HIV-1 Protease Inhibitor: nelfinavir*; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ nelfinavir ↑ M8 metabolite of nelfinavir ↓ lopinavir; … |
| Neratinib | drug interactions | Concomitant Drug Class/Drug Name: Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine; … |
| Nevirapine | drug interactions | Concomitant Drug Class/Drug Name: Non-nucleoside Reverse Transcriptase Inhibitors: efavirenz*, nevirapine*; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ lopinavir; … |
| Nicardipine | drug interactions | Concomitant Drug Class/Drug Name: Dihydropyridine Calcium Channel Blockers: e.g. felodipine, nifedipine, nicardipine; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ dihydropyridine … |
| Nifedipine | drug interactions | Concomitant Drug Class/Drug Name: Dihydropyridine Calcium Channel Blockers: e.g. felodipine, nifedipine, nicardipine; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ dihydropyridine … |
| Nilotinib | drug interactions | Concomitant Drug Class/Drug Name: Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine; … |
| Omeprazole | drug interactions | … probe), etravirine, pitavastatin, pravastatin, stavudine, lamivudine, omeprazole, raltegravir, ranitidine, or rilpivirine. |
| Phenobarbital | drug interactions | Concomitant Drug Class/Drug Name: Anticonvulsants: carbamazepine, phenobarbital, phenytoin; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ lopinavir ↓ phenytoin; … |
| Phenytoin | drug interactions | Concomitant Drug Class/Drug Name: Anticonvulsants: carbamazepine, phenobarbital, phenytoin; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ lopinavir ↓ phenytoin; … |
| Pimozide | contraindications | Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine … |
| Pitavastatin | drug interactions | … interaction between KALETRA and desipramine (CYP2D6 probe), etravirine, pitavastatin, pravastatin, stavudine, lamivudine, omeprazole, raltegravir, ranitidine, or rilpivirine. |
| Pravastatin | drug interactions | … KALETRA and desipramine (CYP2D6 probe), etravirine, pitavastatin, pravastatin, stavudine, lamivudine, omeprazole, raltegravir, ranitidine, or rilpivirine. |
| Prednisolone | drug interactions | … betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ lopinavir ↑ … |
| Prednisone | drug interactions | … ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ lopinavir ↑ glucocorticoids; … |
| Quetiapine | drug interactions | Consider alternative antiretroviral therapy to avoid increases in quetiapine exposures. |
| Quinidine | drug interactions | Concomitant Drug Class/Drug Name: Antiarrhythmics e.g. amiodarone, bepridil, lidocaine (systemic), quinidine; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ antiarrhythmics; … |
| Raltegravir | drug interactions | … etravirine, pitavastatin, pravastatin, stavudine, lamivudine, omeprazole, raltegravir, ranitidine, or rilpivirine. |
| Ranitidine | drug interactions | … pitavastatin, pravastatin, stavudine, lamivudine, omeprazole, raltegravir, ranitidine, or rilpivirine. |
| Ranolazine | contraindications | Alpha 1- Adrenoreceptor Antagonist: alfuzosin Antianginal: ranolazine Antiarrhythmic: dronedarone Anti-gout: colchicine Antipsychotics: lurasidone, pimozide Ergot Derivatives: dihydroergotamine … |
| Rifabutin | drug interactions | Concomitant Drug Class/Drug Name: Antimycobacterial: rifabutin*; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ rifabutin and rifabutin metabolite; … |
| Rifampin | contraindications | Anticancer Agents: apalutamide Antimycobacterial: rifampin Herbal Products: St. John's Wort (hypericum perforatum) Hypersensitivity to KALETRA (e.g., toxic epidermal necrolysis, Stevens-Johnson … |
| Rilpivirine | drug interactions | … pravastatin, stavudine, lamivudine, omeprazole, raltegravir, ranitidine, or rilpivirine. |
| Rivaroxaban | drug interactions | Concomitant Drug Class/Drug Name: Anticoagulants: warfarin, rivaroxaban; Effect on Concentration of Lopinavir or Concomitant Drug: ↑↓ warfarin ↑ rivaroxaban; … |
| Rosuvastatin | drug interactions | Concomitant Drug Class/Drug Name: Lipid-modifying agents HMG-CoA Reductase Inhibitors: lovastatin simvastatin atorvastatin rosuvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor … |
| Salmeterol | drug interactions | Concomitant Drug Class/Drug Name: Long-acting beta-adrenoceptor Agonist: salmeterol; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ salmeterol; … |
| Sildenafil | contraindications | … (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally … |
| Simvastatin | contraindications | … antiviral: elbasvir/grazoprevir HMG-CoA Reductase Inhibitors: lovastatin, simvastatin Microsomal triglyceride transfer protein (MTTP) Inhibitor: lomitapide Non-opioid Analgesic (selective blocker of … |
| Sirolimus | drug interactions | Concomitant Drug Class/Drug Name: Immunosuppressants: e.g. cyclosporine, tacrolimus, sirolimus; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ immunosuppressants; … |
| Sofosbuvir | drug interactions | Concomitant Drug Class/Drug Name: Hepatitis C direct acting antivirals: boceprevir* glecaprevir/pibrentasvir simeprevir sofosbuvir/velpatasvir/voxilaprevir ombitasvir/paritaprevir/ ritonavir and … |
| Sofosbuvir and velpatasvir and voxilaprevir | drug interactions | Hepatitis C direct acting antivirals: boceprevir* glecaprevir/pibrentasvir simeprevir sofosbuvir/velpatasvir/voxilaprevir ombitasvir/paritaprevir/ ritonavir and dasabuvir* ↓ lopinavir ↓ boceprevir ↓ … |
| Sulfamethoxazole and trimethoprim | drug interactions | Based on known metabolic profiles, clinically significant drug interactions are not expected between KALETRA and dapsone, trimethoprim/sulfamethoxazole, azithromycin, erythromycin, or fluconazole. |
| Suzetrigine | contraindications | … Non-opioid Analgesic (selective blocker of Nav1.8 sodium channels): suzetrigine PDE5 Inhibitor: sildenafil (Revatio ® ) when used for the treatment of pulmonary arterial hypertension … |
| Tacrolimus | drug interactions | Concomitant Drug Class/Drug Name: Immunosuppressants: e.g. cyclosporine, tacrolimus, sirolimus; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ immunosuppressants; … |
| Tadalafil | drug interactions | Concomitant Drug Class/Drug Name: PDE5 inhibitors: avanafil, sildenafil, tadalafil, vardenafil; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ avanafil ↑ sildenafil ↑ tadalafil ↑ … |
| Tenofovir disoproxil | drug interactions | Concomitant Drug Class/Drug Name: Nucleoside Reverse Transcriptase Inhibitor: tenofovir disoproxil fumarate*; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ tenofovir; … |
| Trazodone | drug interactions | Concomitant Drug Class/Drug Name: Antidepressant: trazodone; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ trazodone; … |
| Triamcinolone | drug interactions | … dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ lopinavir ↑ glucocorticoids; … |
| Triazolam | contraindications | … the treatment of pulmonary arterial hypertension Sedative/Hypnotics: triazolam, orally administered midazolam KALETRA is contraindicated with drugs that are potent CYP3A inducers where significantly … |
| Vardenafil | drug interactions | Concomitant Drug Class/Drug Name: PDE5 inhibitors: avanafil, sildenafil, tadalafil, vardenafil; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ avanafil ↑ sildenafil ↑ tadalafil ↑ … |
| Venetoclax | drug interactions | Concomitant Drug Class/Drug Name: Anticancer Agents: abemaciclib, apalutamide, encorafenib, ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine; … |
| Vinblastine | drug interactions | … ibrutinib, ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ anticancer agents ↓lopinavir/ritonavir #; … |
| Vincristine | drug interactions | … ivosidenib, dasatinib, neratinib, nilotinib, venetoclax, vinblastine, vincristine; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ anticancer agents ↓lopinavir/ritonavir #; … |
| Voriconazole | drug interactions | Concomitant Drug Class/Drug Name: Antifungals: ketoconazole*, itraconazole, voriconazole isavuconazonium sulfate*; Effect on Concentration of Lopinavir or Concomitant Drug: ↑ ketoconazole ↑ … |
| Warfarin | drug interactions | Concomitant Drug Class/Drug Name: Anticoagulants: warfarin, rivaroxaban; Effect on Concentration of Lopinavir or Concomitant Drug: ↑↓ warfarin ↑ rivaroxaban; … |
| Zidovudine | drug interactions | Concomitant Drug Class/Drug Name: Nucleoside Reverse Transcriptase Inhibitors: abacavir zidovudine; Effect on Concentration of Lopinavir or Concomitant Drug: ↓ abacavir ↓ zidovudine; … |
Other labels that name lopinavir and ritonavir
Source: FDA drug label (Kaletra), AbbVie Inc., effective July 23, 2026 (SPL set 8290add3-4449-4e58-6c97-8fe1eec972e3), via openFDA; the full label on DailyMed
What do FAERS reports show for lopinavir and ritonavir?
The FDA Adverse Event Reporting System holds 13,476 reports that list lopinavir and ritonavir among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,776 are coded as a death and 5,005 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2020 (1,446, against a median of 312 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as lopinavir and ritonavir?
43 other medicines are given the same way (oral) and in the same FDA class as lopinavir and ritonavir or labeled mainly for the same use (HIV), the same class first. HIV lists all 47 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Darunavir | HIV | 13 labelers | $1.16 per tablet 600 mg tablet | No current entry |
| Atazanavir | HIV | 4 labelers | $2.23 per capsule 300 mg capsule | No current entry |
| Cobicistat and darunavir | HIV | none listed | $79.99 per tablet 800 mg-150 mg tablet | No current entry |
| Fosamprenavir | HIV | 2 labelers | n/a | No current entry |
| Nelfinavir | HIV | none listed | n/a | No current entry |
| Atazanavir and cobicistat | HIV | none listed | $52.05 per tablet 300 mg-150 mg tablet | A presentation being discontinued |
| Cobicistat | HIV | none listed | n/a | A presentation being discontinued |
| Cobicistat, darunavir, emtricitabine and tenofovir alafenamide | HIV | none listed | $152.87 per tablet 800-150-200-10 mg tablet | No current entry |
Every medicine labeled for the same conditions as lopinavir and ritonavir
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to lopinavir and ritonavir
- 43 medicines for the same use
- Other cytochrome p450 3a inhibitors
- the pharmacologic class, with prices and generics
- Lopinavir and ritonavir side effects
- the label's list beside FAERS reports
- Lopinavir and ritonavir shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other